QGEN vs. BIIB, BNTX, ARGX, NBIX, TECH, RGEN, PCVX, RVMD, EXEL, and HALO
Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Biogen (BIIB), BioNTech (BNTX), argenx (ARGX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), and Halozyme Therapeutics (HALO). These companies are all part of the "biological products, except diagnostic" industry.
Qiagen (NYSE:QGEN) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.
70.0% of Qiagen shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Biogen has higher revenue and earnings than Qiagen. Biogen is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biogen had 28 more articles in the media than Qiagen. MarketBeat recorded 33 mentions for Biogen and 5 mentions for Qiagen. Qiagen's average media sentiment score of 0.97 beat Biogen's score of 0.42 indicating that Qiagen is being referred to more favorably in the media.
Biogen received 1533 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 71.93% of users gave Biogen an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Qiagen has a net margin of 17.38% compared to Biogen's net margin of 12.07%. Biogen's return on equity of 14.83% beat Qiagen's return on equity.
Qiagen presently has a consensus price target of $50.95, indicating a potential upside of 17.77%. Biogen has a consensus price target of $286.50, indicating a potential upside of 27.37%. Given Biogen's stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Qiagen.
Qiagen has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Biogen has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500.
Summary
Biogen beats Qiagen on 12 of the 18 factors compared between the two stocks.
Get Qiagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
